Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
188 CHF | 0.00% | 0.00% | +2.96% |
Summary
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Investment Management & Fund Operators
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.96% | 1.42B | D+ | ||
+31.41% | 12.02B | - | - | |
+14.40% | 3.06B | B- | ||
-8.46% | 1.22B | - | - | |
+1.15% | 616M | - | ||
-10.84% | 579M | - | B+ | |
+35.79% | 577M | - | D+ | |
-4.17% | 492M | - | - | |
+33.85% | 488M | - | - | |
+3.90% | 304M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HBMN Stock
- Ratings HBM Healthcare Investments AG